Is Torrent Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers
- October 13, 2026
- Posted by: Neeraj Pandey
- Category: Market
Torrent Pharmaceuticals CMP Rs 4,662 (12 Oct 2026). Market cap Rs 1,77,251 Cr. ROE 25.49%. P/E 82.22x versus Industry P/E 36.69x.
Quick Answer
Torrent Pharmaceuticals is one of the names investors compare when screening the Healthcare sector, built on a 25.49% return on equity and a P/E of 82.22x against an Industry P/E of 36.69x. Whether Torrent Pharmaceuticals is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Torrent Pharmaceuticals the best stock in its sector? The stock trades on the NSE at Rs 4,662 as of 12 October 2026, within its 52-week range of Rs 3,480.60 to Rs 5,250.00. Torrent Pharmaceuticals Ltd, headquartered in Ahmedabad and part of the Torrent Group, is an Indian pharmaceutical company with branded generics in India and in international markets.
Torrent Pharmaceuticals sits in the Healthcare sector, and its 25.49% ROE and 82.22x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Torrent Pharmaceuticals
Torrent Pharmaceuticals Ltd, headquartered in Ahmedabad and part of the Torrent Group, is an Indian pharmaceutical company with branded generics in India and in international markets. Branded generics are its core business. The stock trades about 11 percent below its 52-week high and about 34 percent above its 52-week low. At a market capitalisation of Rs 1,77,251 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Torrent Pharmaceuticals the Best Stock in Its Sector?
Torrent Pharmaceuticals makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 25.49% ROE with an 82.22x P/E against the sector’s 36.69x Industry P/E. Torrent Pharma’s 82.22x P/E is more than double the 36.69x Industry P/E, supported by a 25.49% ROE, though a 21.08 P/B and a debt to equity ratio of 1.79 show how much growth is already priced in.
| Metric | Torrent Pharmaceuticals |
|---|---|
| CMP (NSE) | Rs 4,662.00 |
| 52-Week High / Low | Rs 5,250.00 / Rs 3,480.60 |
| Market Cap | Rs 1,77,251 Cr |
| P/E (TTM) vs Industry P/E | 82.22x vs 36.69x |
| P/B | 21.08 |
| ROE | 25.49% |
| EPS (TTM) | Rs 56.68 |
| Dividend Yield | 0.73% |
| Debt to Equity | 1.79 |
Compare Torrent Pharmaceuticals Against Other Healthcare Sector Stocks
How Torrent Pharmaceuticals Compares Against Its Healthcare Sector Peers
The table below sets Torrent Pharmaceuticals against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Torrent Pharmaceuticals | 1,77,251 | 82.22 | 25.49% | 1.79 |
| Sun Pharma | 4,21,539 | 34.79 | 13.74% | 0.06 |
| Cipla | 1,05,290 | 31.37 | 11.27% | 0.02 |
| Peer average (2 companies) | – | 33.08 | 12.50% | 0.04 |
Against this peer set, Torrent Pharmaceuticals’s 25.49% ROE is above the 12.50% peer average, and its P/E of 82.22x runs above the peer average of 33.08x. Torrent Pharma’s 82.22x P/E is more than double the 36.69x Industry P/E, supported by a 25.49% ROE, though a 21.08 P/B and a debt to equity ratio of 1.79 show how much growth is already priced in.
What Makes Torrent Pharmaceuticals Worth Watching in Healthcare
- High returns: A 25.49% ROE is higher than both pharma peers shown here.
- Rich valuation: An 82.22x P/E is more than double the 36.69x Industry P/E.
- Leverage: A debt to equity ratio of 1.79 is higher than Sun Pharma and Cipla in the peer table.
Torrent Pharmaceuticals Valuation: Is It Justified?
Torrent Pharma’s 82.22x P/E is more than double the 36.69x Industry P/E, supported by a 25.49% ROE, though a 21.08 P/B and a debt to equity ratio of 1.79 show how much growth is already priced in. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Lupin the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Torrent Pharmaceuticals and other Healthcare sector stocks.
How to Track Torrent Pharmaceuticals Before You Invest
Before deciding whether Torrent Pharmaceuticals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Torrent Pharmaceuticals to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Torrent Pharmaceuticals earns a place in the best stock in its sector conversation on the strength of a 25.49% ROE and a P/E of 82.22x against a 36.69x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Torrent Pharmaceuticals the best stock in its sector?
Ans. Torrent Pharmaceuticals has a 25.49% ROE and trades at 82.22x P/E against a 36.69x Industry P/E, and compares above the peer average ROE of 12.50% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Torrent Pharmaceuticals?
Ans. Torrent Pharmaceuticals was trading at Rs 4,662.00 on the NSE as of 12 October 2026, within its 52-week range of Rs 3,480.60 to Rs 5,250.00.
What sector does Torrent Pharmaceuticals belong to?
Ans. Torrent Pharmaceuticals is classified under the Healthcare sector on Univest.
How does Torrent Pharmaceuticals compare to its sector peers on P/E?
Ans. Torrent Pharmaceuticals’s P/E of 82.22x is above the 33.08x average of the 2 named peers compared in this article.
What is Torrent Pharmaceuticals’s return on equity?
Ans. Torrent Pharmaceuticals reported a return on equity of 25.49%, which is above the 12.50% average of its named peers in this comparison.
Should I invest in Torrent Pharmaceuticals based on its sector position?
Ans. Torrent Pharmaceuticals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
